T1高级别非肌层浸润性膀胱癌BCG免疫治疗的统计治愈定义
多机构回顾性队列纳入1403例接受充分BCG治疗的T1HG NMIBC患者,采用混合治愈模型计算治愈分数。无复发生存、无进展生存、癌症特异生存和总生存的治愈分数分别为41%、71%、76%和38%;5年无事件者后续5年条件生存概率均超90%。
要点
- BCG治疗T1HG NMIBC的进展治愈分数约71%,癌症特异治愈分数76%。
- 极高危亚组进展和癌症特异治愈分数更低,分别为61%和59%。
- 5年无事件患者后续5年条件生存概率超90%,不良事件风险低于10%。
核心结论
- BCG免疫治疗可使部分T1HG NMIBC患者达到统计治愈,约70%避免进展为肌层浸润性膀胱癌。
- 5年无事件患者后续发生复发、进展或死亡的风险低于10%。
研究设计与样本
- 多机构回顾性队列研究,纳入2007至2020年间1403例接受充分BCG治疗的T1HG NMIBC患者。
- 充分BCG定义为至少5/6诱导剂量和至少2/3维持剂量,并遵循现代指南包括强制二次经尿道膀胱肿瘤电切。
- 采用混合治愈模型计算治愈分数,并计算5年条件生存概率。
主要发现
- 无复发生存治愈分数41%(95%CI 36%-46%),无进展生存71%(95%CI 65%-76%)。
- 癌症特异生存治愈分数76%(95%CI 70%-83%),总生存38%(95%CI 28%-49%)。
- 欧洲泌尿外科协会极高危亚组无进展生存治愈分数61%(95%CI 50%-72%),癌症特异生存59%(95%CI 34%-84%)。
- 5年无事件患者后续5年条件无复发生存、无进展生存、癌症特异生存和总生存概率均超过90%。
关键数值与推荐
- 治愈分数定义为永不发生兴趣事件的患者比例。
- 无复发生存治愈分数41%(95%CI 36%-46%)。
- 无进展生存治愈分数71%(95%CI 65%-76%)。
- 癌症特异生存治愈分数76%(95%CI 70%-83%)。
- 总生存治愈分数38%(95%CI 28%-49%)。
临床怎么用
- 可为T1HG NMIBC患者BCG治疗后的长期预后咨询提供统计治愈概率参考。
- 极高危亚组治愈分数较低,提示需更密切随访或强化治疗策略。
- 5年无事件患者后续不良肿瘤学事件风险低,可考虑调整随访强度。
局限性
- 回顾性多机构队列设计可能存在选择偏倚。
- 统计治愈为模型估计值,需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess cure fraction and conditional survival probabilities for oncological outcomes in patients with T1 high-grade (T1HG) non-muscle-invasive bladder carcinoma (NMIBC) treated with adequate Bacillus Calmette-Guérin (BCG) immunotherapy. PATIENTS AND METHODS: This multi-institutional retrospective cohort study included 1403 patients with T1HG NMIBC treated between 2007 and 2020, adhering to modern guidelines including mandatory second transurethral resection of bladder tumour and adequate BCG, defined as at least five of six induction doses and at least two of three maintenance doses. Cure fraction, defined as the proportion of patients who will never experience the event of interest, was calculated for recurrence-free survival (RFS), progression-free survival (PFS), cancer-specific survival (CSS) and overall survival (OS) using a mixture cure model. Conditional survival probabilities over 5 years were also computed. RESULTS: Cure fractions were 41% (95% confidence interval [CI] 36%-46%) for RFS, 71% (95% CI 65%-76%) for PFS, 76% (95% CI 70%-83%) for CSS, and 38% (95% CI 28%-49%) for OS. Patients in very-high-risk subgroups, according to the European Association of Urology risk stratification, showed significantly lower cure fractions, particularly for PFS (61% [95% CI 50%-72%]) and CSS (59% [95% CI 34-84%]). Conditional survival analysis demonstrated that patient prognoses improved over time, with 5-year conditional RFS, PFS, CSS and OS probabilities exceeding 90% for patients who were event-free at 5 years from diagnosis. CONCLUSIONS: We found that BCG immunotherapy achieves a statistical cure in select T1HG NMIBC patients, with avoidance of progression to muscle-invasive bladder carcinoma in approximately 70% of cases. The probability of experiencing any adverse oncological event (recurrence, progression or death) is less than 10% among patients who remain event-free for 5 years.
引用
- Subiela JD, de la Parra I, Taborda J, et al. Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy. BJU Int. 2025. PMID: 40883258. doi:10.1111/bju.16913
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。